Beijing reported hitting its annual GDP growth targets, but international economists cite weak domestic demand and deflating consumer metrics as evidence of deeper systemic strain.

Chinese industrial enterprises recorded a sharp acceleration in profit growth in September, supported by policy support and resilient high-tech manufacturing output.

Bayer has gained regulatory clearance in China for its novel stroke-prevention medication, capturing a global first-in-class approval as it rebuilds its cardiovascular pipeline.